SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in …
WEB1 day ago · References: Kim HK, Biessels GJ, Yu MH, et al. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. 2024 Oct 22;103(8):e209805. doi:10. ...
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
WEB3 days ago · A total of 6,837 people, or just less than 2%, went on to develop dementia or Parkinson’s disease during the study. The incidence rate for people taking SGLT2 inhibitors who developed Alzheimer ...
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
WEB3 days ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... Alzheimer’s disease among people on SGLT2 inhibitors was just under 40 cases per 10,000 ...
Some diabetes drugs tied to lower risk of dementia, Parkinson's …
WEB3 days ago · For vascular dementia, which is dementia caused by vascular disease, the incidence rate for people taking the SGLT2 drugs was 10.6 cases per 10,000, compared to 18.7 for those taking the other drugs.
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in …
WEB3 days ago · SGLT2i use was associated with a reduced risk for Alzheimer disease, vascular dementia, and Parkinson disease (adjusted hazard ratios, 0.81, 0.69, and 0.80, respectively), with a 6-month drug use ...
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
WEBSep 2, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
FDA Update: Sotagliflozin Approved For Broad HF Treatment
WEBJun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
WEBJun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
Applications of SGLT2 inhibitors beyond glycaemic control
WEBApr 26, 2024 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression in people with or without diabetes as well as the risk of acute kidney injury and...
FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and ... - Pfizer
WEBDec 22, 2017 · Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved STEGLATRO™ (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) tabl...
Skip to content